Lipid Nanoparticles for Linear DNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene delivery systems, particularly non-viral and viral vectors, face challenges such as poor tissue penetration, non-specific cell binding, inflammatory responses, and immune reactions, along with limitations in cargo size and stability, especially when delivering linear DNA molecules for therapeutic applications.
Innovation Solution
Development of nanoparticles comprising a linear DNA molecule, a lipid component, and a targeting peptide, which are self-assembled to enhance resistance to nuclease digestion and improve targeting specificity, allowing for efficient and cost-effective delivery of larger nucleic acid cargo to target cells with reduced immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used for gene delivery, then transfection efficiency and cell selectivity are improved, but toxicity, immune response, and insertional mutagenesis risk increase
Solution Approach 1:
The patent uses lipid-based nanoparticles as intermediary carriers to deliver linear DNA molecules to target cells, avoiding direct viral infection while maintaining transfection efficiency. The lipid component forms protective complexes with the DNA cargo, enabling cellular uptake without triggering viral immune responses or insertional mutagenesis
Solution Approach 2:
The invention employs non-viral, synthetic lipid-DNA nanoparticles that are inexpensive to produce and do not persist in the body like viral vectors. These disposable nanoparticles deliver their cargo and are cleared by the body, avoiding long-term toxicity and immune sensitization associated with viral delivery systems
2Reliability
If plasmid DNA is used for gene therapy, then delivery capability is improved, but bacterial backbone and antibiotic resistant genes cause toxicity and immune response
Solution Approach 1:
The patent extracts only the essential therapeutic gene sequence from the plasmid structure, delivering it as a naked linear DNA molecule without the bacterial backbone, origin of replication, or antibiotic resistance markers. This extraction eliminates all bacterial contaminants and harmful genetic elements while retaining the therapeutic function
Solution Approach 2:
The invention applies local quality by providing different structural contexts for different DNA regions: the therapeutic gene sequence is delivered as a linear molecule optimized for nuclear entry and expression, while all bacterial elements are completely removed rather than modified
3Object-affected harmful factors
If anionic lipid is used as delivery agent, then cytotoxicity is reduced and targeting specificity is improved, but self-assembly of complexes becomes challenging due to negative charges
Solution Approach 1:
The patent merges the anionic lipid component with complementary cationic or zwitterionic components to form charge-balanced nanoparticles. This combination allows the anionic lipid to provide low cytotoxicity and improved targeting while the other components facilitate self-assembly through electrostatic interactions, solving both problems simultaneously
Solution Approach 2:
The invention uses composite lipid materials combining anionic lipids with other lipid types to create nanoparticles with optimized properties. The composite structure provides the benefits of anionic lipids (low toxicity, good targeting) while the combined material enables stable self-assembly and complex formation with the DNA cargo
4Quantity of substance
If linear DNA molecule is used for gene therapy, then cargo size is improved, but resistance to nuclease digestion is reduced compared to plasmid DNA
Solution Approach 1:
The patent applies preliminary protection by coating the linear DNA molecule with lipid components before delivery, creating a protective complex that shields the DNA from nucleases in the bloodstream and cellular environment. This preliminary protective action enables the linear DNA to reach the nucleus intact despite its inherent nuclease susceptibility
Solution Approach 2:
The lipid nanoparticle acts as an intermediary protective layer between the vulnerable linear DNA and the nuclease-rich biological environment. This intermediary structure allows the linear DNA to benefit from large cargo capacity while being protected from degradation during circulation and cellular uptake
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles provide prolonged in vivo stability and efficient transfection of linear DNA molecules into target cells, offering improved safety and scalability for therapeutic applications by minimizing immune responses and enabling larger cargo delivery.
Implementation Method 1
Development of nanoparticles comprising a linear DNA molecule, a lipid component, and a targeting peptide, which are self-assembled to enhance resistance to nuclease digestion
Implementation Method 2
Non-viral gene delivery systems are based on the compaction of genetic material into nanometric particles by electrostatic interaction between the negatively charged phosphate backbone of DNA and cationic lipids, peptides or other polymers
Data Source
AI summary
Nanoparticles suitable for delivery of a linear DNA molecule (e.g. a closed linear DNA molecule) to a target cell are provided. Further provided are uses of the nanoparticles including the use of the nanoparticles for treating disease.